Centre Signs Deal To Get 2nd Made-In-India Vaccine, 30 Crore Doses Booked
NDTV
The doses will be manufactured and stockpiled by Biological-E from August to December 2021, says the ministry.
Aiming at a huge vaccination target, the government has booked 30 crore doses of Hyderabad-based Biological-E's Covid vaccine, which is still in clinical trials. The Health Ministry will make an advance payment of Rs 1,500 crore to the company for what will be the second made-in-India vaccine to be used in the country after Bharat Biotech's Covaxin. The doses will be manufactured and stockpiled by Biological-E from August to December 2021, says the ministry. The move comes after massive criticism of the Centre's vaccination policy, which fell short when India was hit by a fierce second wave of Covid in March-April. The government had to pause exports of Covid shots under its "Vaccine Maitri" programme and scrambled to procure more doses to tackle shortage in the country. Biological-E's vaccine is currently in Phase-3 clinical trials after showing promising results in Phase 1 and 2, said the government in a statement.More Related News